Results 41 to 50 of about 7,243,041 (296)
The company size as a determinant of financial result [PDF]
In different studies examined the determinants that significantly determine a company's financial performance. The size of the company is often mentioned as a determinant of the financial result.
Ševkušić Ljubiša
doaj +1 more source
Synergistic perspectives—How single‐molecule biophysics complement biochemical understanding
In this review, we discuss how ensemble biochemistry and single‐molecule approaches are complementary, outline commonly used single‐molecule techniques, and illustrate their relevance through two representative case studies: chromatin organization by SMC complexes and pathway choice during DNA double‐strand break repair.
Sara De Bragança +2 more
wiley +1 more source
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
The Influence of Profitability, Company Size and Leverage on Company Value
This study aims to explain the significance of the effect of profitability, company size and leverage partially on the value of property companies listed on the IDX. This study took a sample of 10 companies during the research period, namely 2018-2020 using the purposive sampling method with the criteria of sub-food & beverage manufacturing ...
Hidayat, Imam, Wati, Dwi Setia
openaire +2 more sources
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park +6 more
wiley +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
From Sleeve: Stieff Piano Company. Branch Series. (14435). N645.Charles M. Stieff Piano Company, No. 9 Liberty Street, BALTIMORE, MDTitle supplied by cataloger.Positive digital file from original glass negative.Some paper adhered to emulsion, some spots ...
Hughes Company
core +1 more source
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico +5 more
wiley +1 more source
Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson +2 more
wiley +1 more source
ESG disclosure and company profitability: Does company size play a role?
Purpose — This study aims to examine the relationship between Environmental, Social, and Governance (ESG) disclosures and profitability, with firm size as a moderating variable.
Risal Risal +2 more
doaj +1 more source

